Literature DB >> 21044268

Novel peptide inhibiting both TEM-1 β-lactamase and penicillin-binding proteins.

Denis Phichith1, Sylvie Bun, Severine Padiolleau-Lefevre, Adeline Guellier, Soun Banh, Moreno Galleni, Jean-Marie Frere, Daniel Thomas, Alain Friboulet, Berangere Avalle.   

Abstract

9G4H9, a catalytic antibody displaying β-lactamase-like activity, has been developed by the anti-idiotypic approach using β-lactamase as the first antigen. Thus 9G4H9 represents the 'internal image' of β-lactamase. We selected a cyclic peptide anchored to a bacteriophage M13 library using 9G4H9 as the target. Pep90 is a cyclic heptapeptide enclosed between two cysteine residues. We showed that Pep90 could inhibit both TEM-1 β-lactamase (K(i)  = 333 μm) and several penicillin-binding proteins (IC₅₀ values ranging from 6-62 μm). We determined that the tryptophan residue of Pep90 is of crucial importance for its inhibitory activity. Using Pep90 as a scaffold, we generated a new class of peptidomimetics that retained inhibitory activity towards TEM-1 β-lactamase.
© 2010 The Authors Journal compilation © 2010 FEBS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044268     DOI: 10.1111/j.1742-4658.2010.07906.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  3 in total

1.  Spectroscopic analysis and docking simulation on the recognition and binding of TEM-1 β-lactamase with β-lactam antibiotics.

Authors:  Jianting Yang; Qian Li; Liujiao Bian
Journal:  Exp Ther Med       Date:  2017-07-31       Impact factor: 2.447

2.  Structural and Functional Mise en Abyme.

Authors:  Bérangère Avalle; Séverine Padiolleau-Lefevre; Alain Friboulet
Journal:  Front Mol Biosci       Date:  2019-11-28

Review 3.  Development of new drugs for an old target: the penicillin binding proteins.

Authors:  Astrid Zervosen; Eric Sauvage; Jean-Marie Frère; Paulette Charlier; André Luxen
Journal:  Molecules       Date:  2012-10-24       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.